Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.

EyeWorld Weekly, November 21, 2025

➤ 510(k) clearance granted to auto kerato-refracto tonometer ➤ First patient dosed with gene therapy for Best disease ➤ Long-term data shows therapy delays geographic atrophy progression ➤ Lead gene therapy candidate to treat wet AMD and DME announced ➤ FDA accepts BLA resubmission ➤ Company news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, November 21, 2025

EyeWorld Weekly, November 14, 2025

➤ Meeting with FDA to advance therapy for Leber congenital amaurosis ➤ 36-month data from first-in-human bimatoprost-IOL system ➤ 20-week data from study evaluating treatment for patients with macular edema secondary to inflammation ➤ Interim data from Phase 1/2 trial for wet AMD therapy ➤ Company news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, November 14, 2025

EyeWorld Weekly, November 7, 2025

➤ Topline Phase 3 results for low-dose atropine drop ➤ 12-month data from prospective pilot study assessing aqueous shunt ➤ 5-year follow-up data supports safety, tolerability of investigational retinitis pigmentosa treatment. ➤ Randomization achieved in registrational trial for wet AMD therapy ➤ BLA submitted for thyroid eye disease treatment ➤ Company news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, November 7, 2025

EyeWorld Weekly, October 31, 2025

➤ Complete response letter issued for low-dose atropine drop ➤ Extension study shows reduced GA growth with intravitreal treatment ➤ Durable, 3-year vision improvements seen with optogenetic therapy ➤ Preclinical data supports long-acting nature of investigational anti-VEGF for wet AMD ➤ Company news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, October 31, 2025

EyeWorld Weekly, October 24, 2025

➤ FDA approves epithelium-on crosslinking treatment ➤ 12-month results from Phase 1/2 trial evaluating regenerative cell therapy for corneal endothelial disease ➤ Phase 3 data supports nonsteroidal treatment for uveitic macular edema ➤ FDA approves IDE for glaucoma device ➤ Company news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, October 24, 2025

EyeWorld Weekly, October 17, 2025

➤ New trifocal receives FDA approval ➤ Robotic system completes its first cataract surgery ➤ Interim results from first-in-human bimatoprost-IOL system ➤ Reproducible regenerative effects observed in preclinical glaucoma model ➤ Phase 3 program begins for intravitreal insert treating wet AMD, DME ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, October 17, 2025

EyeWorld Weekly, October 10, 2025

➤ Insulin-based treatment for neurotropic keratitis advances ➤ Study evaluating implantable telescope in patients with late-stage AMD begins ➤ Registrational trial to begin for investigational neuroprotective therapy ➤ Enrollment complete in pivotal trials for wet AMD treatment ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, October 10, 2025

EyeWorld Weekly, October 3, 2025

➤ Phase 1/2 trial update for Leber congenital amaurosis gene therapy in pediatric patients ➤ Primary endpoint not met in Phase 2b trial investigating persistent corneal epithelial defect treatment ➤ Study: treatment for uveal melanoma could improve survival rate ➤ Company news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, October 3, 2025

EyeWorld Weekly, September 26, 2025

➤ Priority review granted to possible LHON treatment ➤ Update on drug in development for neuropathic corneal pain ➤ FDA approves generic bimatoprost ➤ Phase 1/2a clinical results for first-in-human retinal pigment epithelial stem cell therapy ➤ Adult dosing complete in trial for X-linked retinoschisis therapy ➤ Company news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, September 26, 2025